دورية أكاديمية

Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies.

التفاصيل البيبلوغرافية
العنوان: Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies.
المؤلفون: Brunet, Salut, Urbano-Ispizua, Alvaro, Ojeda, Emilio, Ruiz, Dolores, Moraleda, José Ma., Díaz, Miguel Angel, Caballero, Dolores, Bargay, Joan, de la Rubia, Javier, Solano, Carlos, Zuazu, Javier, Diez, José Luis, de la Serna, Javier, Espigado, Idelfonso, Alegre, Adrián, Torres, J. Pio, Jurado, Manuel, Fernández, Manuel, Vivancos, Pilar, Carreras, Enric
المصدر: British Journal of Haematology; Sep2001, Vol. 114 Issue 3, p544-550, 7p, 4 Charts, 2 Graphs
مصطلحات موضوعية: GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, HEMATOLOGICAL oncology
مستخلص: To assess the influence of graft-versus-host disease (GVHD) on the outcome of patients with advanced haematological malignancies (AHM) who received a primary, unmodified allogeneic peripheral blood progenitor cells transplant (allo-PBT) from a human leucocyte antigen (HLA) identical sibling donor, we analysed 136 patients with myeloid neoplasms (n = 70) or lymphoproliferative disorders (n = 66), transplanted at 19 Spanish institutions. Median age was 35 years (range 1–61). The cumulative incidence of relapse for all patients was 34% (95% CI, 26–42%), 41% (95% CI, 33–49) for patients without GVHD and 14% (95% CI, 3–25) (P = 0·001) for patients with acute and chronic GVHD. After a median follow-up of 11 months (range 2–49), 60 (44%) patients remained alive with an actuarial probability of overall survival and disease-free survival (DFS) at 30 months of 31% (95% CI, 21–41%) and 28% (95% CI, 17–39%) respectively. In patients surviving > 100 d, the low incidence of relapse in those with acute and chronic GVHD led to a DFS of 57% (95% CI, 38–76%) compared with a DFS of 34% (95% CI, 17–51%) in the remaining patients (P = 0·03). Our results indicate a reduced incidence of relapse for patients with AHM receiving an unmodified allo-PBT and developing acute and chronic GVHD, which results in an improved DFS. [ABSTRACT FROM AUTHOR]
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00071048
DOI:10.1046/j.1365-2141.2001.03002.x